X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 29.4 22.1 132.9% View Chart
P/BV x 3.7 3.1 120.2% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-18
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs695176 395.1%   
Low Rs40079 509.6%   
Sales per share (Unadj.) Rs260.237.7 690.4%  
Earnings per share (Unadj.) Rs19.05.1 372.5%  
Cash flow per share (Unadj.) Rs33.16.7 491.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.042.5 500.7%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.13.4 62.3%   
Avg P/E ratio x28.925.0 115.6%  
P/CF ratio (eoy) x16.618.9 87.5%  
Price / Book Value ratio x2.63.0 86.0%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,12020,135 343.3%   
No. of employees `00013.31.2 1,150.5%   
Total wages/salary Rs m7,359703 1,046.5%   
Avg. sales/employee Rs Th2,477.45,176.2 47.9%   
Avg. wages/employee Rs Th555.2610.4 91.0%   
Avg. net profit/employee Rs Th180.6699.6 25.8%   
INCOME DATA
Net Sales Rs m32,8365,963 550.7%  
Other income Rs m41818 2,322.2%   
Total revenues Rs m33,2545,981 556.0%   
Gross profit Rs m4,5051,430 315.0%  
Depreciation Rs m1,777258 689.1%   
Interest Rs m240-26 -923.8%   
Profit before tax Rs m2,9051,216 238.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m511342 149.4%   
Profit after tax Rs m2,394806 297.1%  
Gross profit margin %13.724.0 57.2%  
Effective tax rate %17.628.1 62.5%   
Net profit margin %7.313.5 54.0%  
BALANCE SHEET DATA
Current assets Rs m19,4555,102 381.3%   
Current liabilities Rs m10,0762,385 422.4%   
Net working cap to sales %28.645.6 62.7%  
Current ratio x1.92.1 90.3%  
Inventory Days Days98150 65.2%  
Debtors Days Days67113 59.1%  
Net fixed assets Rs m20,2605,148 393.5%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m26,6336,556 406.3%   
Net worth Rs m26,8866,732 399.4%   
Long term debt Rs m2,340952 245.8%   
Total assets Rs m41,17310,388 396.4%  
Interest coverage x13.1-45.8 -28.6%   
Debt to equity ratio x0.10.1 61.5%  
Sales to assets ratio x0.80.6 138.9%   
Return on assets %6.47.5 85.2%  
Return on equity %8.912.0 74.4%  
Return on capital %10.814.6 73.7%  
Exports to sales %47.674.5 64.0%   
Imports to sales %14.924.8 60.0%   
Exports (fob) Rs m15,6424,441 352.3%   
Imports (cif) Rs m4,8841,477 330.6%   
Fx inflow Rs m15,6425,298 295.3%   
Fx outflow Rs m4,8841,772 275.6%   
Net fx Rs m10,7593,525 305.2%   
CASH FLOW
From Operations Rs m3,4111,274 267.7%  
From Investments Rs m-1,354-1,204 112.4%  
From Financial Activity Rs m-1,304-196 665.0%  
Net Cashflow Rs m753-126 -596.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Dec 17, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS